Search Results

Strong GPCR drug discovery decisions are built on structure, early risk awareness, and focused signal detection. If you work in GPCR research, clarity is leverage. The ability to access the right framework, detect risk early, and act on emerging signals determines whether programs accelerate—or stall. This week’s issue focuses on structure, early safety strategy, and the next wave of signal transduction research. Each piece is designed to help you make better decisions—faster. 🔍 This Week in Premium: Sneak Peek Industry insights: Confo nominates SSTR5 agonist antibody CFTX-2034; Lilly oral GLP-1 maintenance data; Enveda IND clearance ENV-308; Zealand explores brain-directed obesity therapies. Upcoming events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug Discovery Summit. Career opportunities: Senior Scientist roles; Postdoctoral GPCR positions. Must-read publications: D2 receptor constitutively active mutants; β2AR allosteric SERS assay; CXCR4 inhibitor burixafor Phase 2. Dr. GPCR University — Reorganized for Clarity and Speed The Dr. GPCR University has undergone a structural redesign. This soft launch prioritizes usability and clarity to support stronger GPCR drug discovery decisions across teams. You can now search courses by level, topic, or instructor. Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages. Full course videos stream directly from the platform, and downloadable resources are available in one place. Legacy courses will migrate into this format over the coming weeks, with live courses returning in March. In the meantime, Premium members continue to have full access to the legacy course pages. Why this matters now: Stop wasting time hunting for relevant training across fragmented platforms. Align your team around structured learning outcomes, not scattered slide decks. Identify the exact knowledge gap slowing your program—and close it efficiently. All courses remain included in Premium Membership. Preview the full University experience ➤ Already a Premium Member? Start learning here ➤ Terry’s Corner — Early Safety Assays For Better GPCR Drug Discovery Decisions Too many discovery programs fail because early safety signals were underestimated—or missed entirely. In this session, Dr. Terry Kenakin walks through the core early assays that protect your chemistry, budget, and timeline. This is not theory. It is operational pharmacology designed to prevent avoidable setbacks. Early safety frameworks directly influence GPCR drug discovery decisions, especially when timelines and capital are tight. What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags. Interpret cytotoxicity data correctly—distinguish transient stress from meaningful off-target damage. Assess hepatotoxicity risk—anticipate reactive metabolites and high-risk drug–drug interactions. Since launch, Terry’s Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics, efficacy, mechanism, ADME, and experimental design. It delivers repeatable depth far beyond a short-format workshop. An upcoming live Ask-Me-Anything (AMA) with Dr. Kenakin takes place February 26 at 12:00 PM EST. Subscribe to the free Kenakin Brief Newsletter to join the AMA . Premium Members get 50%+ discount when they join Terry’s Corner. Access this week’s safety framework ➤ GPCRs: Signal Transduction — Volume II (Call for Papers, Deadline March 14) Signal transduction remains central to understanding GPCR biology across health and disease. A new volume dedicated to GPCR signal transduction invites contributions spanning cellular biochemistry, mechanistic signaling, and translational implications. Submissions are welcome across formats including Original Research, Reviews, Methods, Perspectives, Hypothesis and Theory, Technology and Code, and more. This initiative brings together field experts to advance collective understanding of how GPCR-mediated signaling shapes physiology and pathology. Given the pace of mechanistic and structural insight emerging across the field, coordinated scholarly contribution is timely. Why consider contributing: Position your work within a focused, visible GPCR signaling collection. Contribute to shaping scientific direction in cellular biochemistry. Strengthen field-wide dialogue around signaling mechanisms and dysfunction. Submit your work today ➤ Why Dr. GPCR Premium Membership Gives You an Edge GPCR science is accelerating across obesity, CNS, oncology, and metabolic disease. More data. More companies. More noise. Premium Membership filters that complexity — without filtering out what matters. Each week, you receive curated, signal-focused intelligence: industry developments, classified publications, priority event tracking, curated career opportunities, and full access to Dr. GPCR University courses — now included in Premium. That means structured, searchable, expert-led training across levels and topics — without additional course fees. Premium Members also receive a 50%+ discount on Terry’s Corner , unlocking advanced pharmacology depth and live AMAs with Dr. Terry Kenakin at a significantly reduced cost. This is not commentary. It is structured access and structured education. Premium supports more confident GPCR drug discovery decisions by helping you: Detect meaningful shifts early — without wading through noise. Strengthen mechanistic understanding through organized expert frameworks. Equip your team with repeatable training resources in one place. Reduce external training spend while increasing scientific depth. It supports scientists refining expertise. It strengthens teams executing discovery programs. It equips leaders making strategic and capital decisions. When decisions compound, scattered information creates drag.Structured access creates momentum. Premium delivers that — consistently. Explore Premium Today ➤

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before anyone notices that strategy has begun to drift. In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Founders tell themselves that certain compromises are temporary, that clarity will return after the round closes. 👉 What actually happens is more subtle. Urgency replaces direction, and short-term signaling begins to outweigh long-term thinking. This is where most biotech startup fundraising mistakes are born, not from lack of intelligence or discipline, but from the belief that fundraising decisions exist outside the core strategy. 👉 In reality, every fundraising-driven adjustment leaves a structural mark on how the company operates, prioritizes, and allocates attention. Over time, these small shifts accumulate. Milestones are chosen for narrative strength rather than strategic leverage. Hiring decisions are pulled forward to support a story. Hard tradeoffs are delayed instead of resolved. 👉 None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech startups. ✅ This post explores why fundraising mistakes have such a disproportionate impact on biotech companies, how these patterns emerge in otherwise well-run teams, and what founders can do to keep fundraising from taking control of their strategy. 👉 If you are preparing to raise, currently fundraising, or reflecting on a recent round, this is an opportunity to recognize where pressure may already be shaping decisions more than strategy should. Fundraising rarely breaks biotech startups overnight. It quietly reshapes decisions, long before the damage becomes visible. Fundraising turns strategy into reaction 👉 Fundraising rarely enters a biotech startup as a strategic decision-making framework. It enters as pressure. Pressure to show progress. Pressure to justify valuation. Pressure to appear confident about the future. And under pressure, even strong teams begin to confuse movement with direction. 👉 In early-stage biotech, this confusion is especially dangerous. Scientific progress already moves slowly, uncertainty is unavoidable, and timelines stretch far beyond what most investors are comfortable with. 👉 When fundraising begins, founders often respond by accelerating visible activity rather than strengthening underlying strategy. This is where one of the most common biotech startup fundraising mistakes takes root. Decisions stop being evaluated based on long-term leverage and start being filtered through a single question. Will this help the raise? 👉 When that question becomes dominant, strategy quietly shifts from intentional design to reactive justification. Teams begin to prioritize what can be explained easily over what actually matters most. Milestones are selected for narrative clarity rather than strategic necessity. Roadmaps bend toward what sounds fundable instead of what creates durable value. 👉 Over time, the company becomes highly responsive but increasingly misaligned. What makes this pattern so hard to catch is that it feels productive. Meetings increase. Slides improve. Activity intensifies. Yet clarity erodes, because reaction has replaced deliberate choice.   👉 Strong biotech startups do not fail at this stage because they stopped working hard. They fail because they stopped deciding with purpose. How biotech startup fundraising mistakes actually show up 👉 Fundraising mistakes rarely appear as obvious errors. In strong biotech startups, they surface as reasonable adjustments that seem aligned with reality. This is what makes them so difficult to recognize while they are happening. 👉 Under fundraising pressure, decision-making slowly shifts. Founders do not deliberately abandon strategy. Instead, they begin to evaluate choices through a narrower lens. What helps the raise starts to matter more than what strengthens the company. 👉 In practice, biotech startup fundraising mistakes most often show up as the following patterns: Milestones are chosen for narrative clarity rather than strategic leverage.   Experiments are prioritized because they fit a clean story, not because they meaningfully reduce scientific or commercial risk. Hiring decisions are accelerated to signal momentum.   Roles are added to demonstrate scale, even when the organization is not structurally ready to support them. Scientific priorities are reshaped to meet investor expectations.   Programs move forward because they sound fundable, not because the data justifies the timing. Hard strategic tradeoffs are postponed.   Founders delay narrowing focus, hoping clarity will emerge after the round instead of designing it upfront. Internal alignment weakens beneath visible progress.   Teams execute faster but understand less clearly why certain priorities exist, creating silent friction. 👉 Each of these decisions can be defended in isolation. The damage comes from their cumulative effect , when short-term fundraising logic quietly replaces deliberate strategy. 👉 This is why strong biotech startups often appear busiest right before they lose momentum. Activity increases, but clarity erodes , and the company becomes reactive instead of intentional. Clarity does not follow funding. Funding follows clarity. Why fundraising mistakes reshape the company before anyone notices Most biotech founders assume that fundraising mistakes show up as visible failures. A missed round. A rejected pitch. A broken investor process. In reality, the most damaging mistakes rarely appear at the surface. 👉 They take shape much earlier, inside the logic of everyday decisions, long before fundraising outcomes are known. Fundraising introduces a specific kind of cognitive pressure. It rewards confidence over uncertainty, clarity over complexity, and momentum over reflection. Under these conditions, decision making begins to shift subtly. Choices that simplify the story are favored over choices that preserve strategic truth. Decisions that reduce tension are prioritized over decisions that resolve it. 👉 The company does not become careless. It becomes selectively blind. As this pattern repeats, the organization adapts. Teams learn which questions are welcomed and which ones slow things down. Scientific nuance starts to feel inconvenient. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often just the absence of friction, and friction disappears not because issues are solved, but because they are avoided. This is how biotech startup fundraising mistakes embed themselves into the operating system of the company. They are not single wrong calls, but accumulated shifts in how decisions are framed and justified. By the time founders sense that something feels off, the logic has already normalized. 👉 The company is still moving, still executing, but no longer questioning the direction with the same rigor. This is why strong biotech startups can lose their strategic center without any dramatic turning point. Nothing breaks all at once. Instead, clarity erodes quietly, decision by decision, under the assumption that everything will be fixed after the round closes. What actually prevents fundraising mistakes from taking over Most biotech founders try to solve fundraising-related problems by improving execution. Better decks. Clearer narratives. Tighter timelines. 👉 What they often miss is that execution quality does not protect strategy when the decision logic itself is unstable. The companies that avoid destructive fundraising mistakes do not do so because they raise faster or pitch better. They do it because they anchor fundraising inside a stronger strategic structure. 👉 That structure usually rests on a small number of non-negotiable principles. 1️⃣ They define strategic truth before investor truth. 👉 High-performing biotech teams are explicit about what must be true for the company to succeed, independent of how attractive that story sounds externally. Fundraising adapts to this reality, not the other way around. 2️⃣ They separate progress from presentation. 👉 These teams distinguish clearly between work that advances the company and work that merely explains it. Investor readiness never becomes the primary filter for scientific or organizational decisions. 3️⃣ They make hard tradeoffs early and visibly. 👉 Instead of postponing narrowing decisions until after a round, they resolve them upfront. This reduces internal ambiguity and prevents fundraising pressure from reopening questions that were already strategically settled. 4️⃣ They protect decision quality under pressure. 👉 As fundraising intensity increases, they slow down decision-making rather than accelerate it. Additional scrutiny is applied exactly where urgency would normally shortcut thinking. What unites these behaviors is not discipline for its own sake, but intent. Fundraising remains a tool, not a steering mechanism.  Strategy continues to shape decisions even when external pressure rises. ✅ This is the point where biotech startup fundraising mistakes stop accumulating. Not because risk disappears, but because decisions remain grounded in a framework that fundraising cannot easily distort. Strategic Takeaway 👉 Strong biotech startups are rarely destroyed by a single bad fundraising decision. They lose their edge when fundraising quietly becomes the logic behind everyday choices , replacing strategy with serving it. 👉 The difference between companies that survive fundraising pressure and those that drift is not discipline or ambition. It is whether decision-making remains anchored in a clear strategic framework before, during, and after the raise . Fundraising should amplify direction, not define it. When strategy leads, and fundraising follows, capital becomes leverage. When fundraising leads and strategy reacts, even strong biotech startups slowly lose coherence. ✅ The real work is not raising better. The real work is deciding clearly before pressure decides for you. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold to a complete halt. Rushing past early safety signals, especially those emerging from cytotoxicity or off-target activities, risks catastrophic consequences for both patient safety and project resources. The pressure mounts further as regulators require detection and characterization of these liabilities—even when they emerge rapidly or unpredictably. The strategic challenge is knowing which early assays are truly non-negotiable, which mechanisms demand immediate attention, and how to build robust decision points into the cascade without falling into the trap of overtesting or false reassurance. In this session, you’ll gain: Clarity on high-impact early safety assays and their compelling rationale Understanding of toxicological mechanisms shaping go/no-go choices Strategic insights into early identification and mitigation of drug liabilities Game-Changing Early Safety Assays Certain toxicological activities, if identified in a compound scaffold, are strategic showstoppers. In the full lecture, Dr. Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such as hERG inhibition or mutation induction—long before a candidate enters the clinic. These tests transform discovery cascades by distinguishing navigable risks from non-starters. Highly selective filters can streamline resource allocation Early elimination of unsafe scaffolds prevents late-stage attrition hERG and Cardiac Risk hERG potassium channel inhibition represents a fatal toxic liability, rapidly precipitating ventricular fibrillation. Dr. Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have evolved to prioritize this critical safety gate. A scaffold exhibiting hERG inhibition is an immediate candidate for discontinuation, as the risk is both acute and universally unacceptable. hERG testing is non-negotiable in early discovery Assay sensitivity balances speed and clinical relevance Mutation Induction and the Ames Test Mutagenicity stands as another barrier. The Ames test, a foundational bacterial assay, surfaces as an early alert for DNA-modifying liabilities. The full lecture describes how this assay serves as a one-way filter: positive results necessitate project termination, while negatives invite further but cautious progression. Single-point thresholds for halting progression Cannot wholly exclude latent risks with a negative result Cytotoxicity and Off-Target Screening Compounds are systematically challenged in vitro against a spectrum of cellular targets—enzymes, receptors, transporters—to expose off-target activities and unintended cytotoxic effects. Dr. Kenakin stresses that multi-parametric cell-based assays highlight hidden threats, from membrane disruption to mitochondrial impairment, demanding robust, multitiered screens in the discovery workflow. Cytotoxicity is multifactorial and mechanism-dependent Early in vitro screens save time by revealing broad liabilities Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of orally administered compounds, remains a sentinel for generalized toxicity. Dr. Kenakin clarifies that both direct hepatotoxic effects and conditional toxicities, such as those driven by drug-drug interactions, must be interrogated at this stage. The emphasis is on predicting and averting the generation of reactive metabolites capable of irreversible harm. Liver-centric assays identify primary and secondary toxic mechanisms Reactive metabolite detection is vital for long-term safety Reactive Metabolites and Irreversible Damage Formation of reactive metabolites that alkylate proteins or nucleic acids can result in permanent organ dysfunction. Dr. Kenakin demonstrates how mechanistic assays allow for early warning, ensuring that compounds prone to generate such species are deprioritized or redesigned before entering expensive development stages. Irreversible modifications pose ongoing risks for safety profiles Proactive detection methodology arms discovery teams with actionable insight Pharmacokinetic and High-Dose Investigations Regulatory guidance requires toxic effects to be observed—if achievable—at sufficiently high concentrations. Pharmacokinetic approaches are adapted, sometimes employing exotic carriers or solvents to maximize exposure. Dr. Kenakin details how discovery teams can leverage atypical conditions to elucidate liabilities and satisfy regulatory scrutiny. Purpose-driven exposure strategies enhance detection Unique pharmacokinetics may be required for robust toxicology In Silico Toxic Signals Advancements in computational screening enable teams to avoid chemotypes associated with known toxicity ("toxicophores"). Dr. Kenakin acknowledges the increasing utility of in silico alerts in early decision-making, arming medicinal chemists and project leaders with tools to preempt costly wet-lab dead ends. Red-flagging toxicophores accelerates rational design cycles Computational prediction complements biological screening Why Terry’s Corner Terry’s Pharmacology Corner delivers weekly in-depth lectures by Dr. Kenakin, monthly live AMAs, and a growing library of on-demand content—all focused on sharpening discovery fundamentals, challenging entrenched assumptions, and strengthening preclinical pipelines. As GPCR science and pharmacological innovation accelerate, timely guidance from foundational to advanced concepts has never been more urgent. 40 years of expertise at your fingertips: Explore the full library ➤ Or preview what’s inside: Read the latest articles ➤ 40 years of expertise at your fingertips : Explore the full library ➤

Discover the Dr. GPCR Ecosystem – the ultimate hub for GPCR professionals to connect, collaborate, and advance drug discovery. Home: About Accelerating GPCR Drug Discovery, Together Dr. GPCR is the global hub where academia and industry meet to advance GPCR research, accelerate drug discovery, and foster collaboration across the entire ecosystem. 👉 Join Free Today 🔒 Go Premium Strategic Partner(s) Your Path to GPCR Mastery Flexible, career-ready courses designed by scientists for scientists. GPCR Courses ➚ Terry's Corner GPCR Weekly News ➚ Dr. GPCR Podcast ➚ Articles from the Ecosystem ➚ Better GPCR Drug Discovery Decisions Start With Structured Learning Why Fundraising Mistakes Kill Strong Biotech Startups Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026 Closing the Gap Between Academia and Industry Our vision is simple: empower the GPCR field through shared knowledge, collaboration, and open access to tools that accelerate drug discovery. 🤝 Support the Mission Home: Premium Premium Yearly $499 $ 499 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Select 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. 🔒 Grandfather Guarantee, your rate never increases Everything You Need to Master GPCR Science in One Membership Join the most complete GPCR learning & collaboration hub. Explore the packages and choose one that works for you Advancing GPCR Science Through Collective Intelligence Dr. GPCR is a living ecosystem where global minds converge to share knowledge, spark collaboration, and shape the future of GPCR-driven discovery. 🤝 Support the Mission

Home Courses Articles About Log In / Sign Up Terry's Pharmacology Corner Lost in GPCR Complexity? Step Into Terry’s Corner Finally, See the Signal 🔥 Watch course | Feb 10, 2026 🔥 Watch the AMA Session | Dec 2, 2025 🔥 Watch the AMA Session | Sept 18, 2025 🔥 Watch course | Oct 7, 2025 🔥 Watch course | Sept 16, 2025 🔥 Watch course | Aug 26, 2025 🔥 Watch course | Aug 5, 2025 🔥 Watch course | July 15, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | Feb 3, 2026 🔥 Watch course | Nov 18, 2025 🔥 Watch course | Oct 21, 2025 🔥 Watch course | Sept 30, 2025 🔥 Watch course | Sept 9, 2025 🔥 Watch course | Aug 19, 2025 🔥 Watch course | July 29, 2025 🔥 Watch course | July 8, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | Dec 9, 2025 🔥 Watch course | Nov 11, 2025 🔥 Watch course | Oct 14, 2025 🔥 Watch course | Sept 23, 2025 🔥 Watch course | Sept 2, 2025 🔥 Watch course | Aug 12, 2025 🔥 Watch course | July 22, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 🔥 Watch course | July 1, 2025 1 2 1 ... 1 2 ... 2 TCBuyCourse Start Learning with Terry 🔥 Upgrade to Premium Terry’s Corner $2,999 $ 2,999 Every year 40 years. One corner. One pricing. Valid until canceled 7 day free trial Select Watch 4 New Courses Each Month Connect in a Private Drug Hunter Hub Skip The Fluff, Learn What Matters Join Monthly AMAs with Terry Unlock 40+ Years of Expertise Master GPCRs with Precision Premium Yearly for Teams $2,249.25 • per year • per person • 25% discount • minimum 5 seats How does it work? 1️⃣ Gather Your Team 2️⃣ Submit Your Team Details 3️⃣ Complete the Payment 4️⃣ Activate Memberships Select Terry’s Pharmacology Corner — Created by Dr. Terry Kenakin , powered by Dr. GPCR . Stay connected on LinkedIn and YouTube . Explore : Foundational Lessons — Build Your Pharmacology Core Emerging Drug Hunter — Expand Your Edge Expert-Level Mastery — Advanced Pharmacology Live AMA Sessions with Terry

Your go-to hub for everything GPCR! Stay ahead with the latest research breakthroughs, industry updates, job opportunities, and upcoming events—all in one place. GPCR Weekly News - Your Hub for GPCR Research, Industry Updates, Jobs & Events Delivered straight to your inbox every week Become a Premium Member Welcome to GPCR Weekly News! Whether you're a GPCR scientist, biotech innovator, or industry professional, GPCR Weekly News keeps you connected to the discoveries and opportunities that matter most. Latest Research Breakthrough discoveries, new publications, and cutting-edge GPCR research insights. Industry Events Upcoming conferences, workshops, webinars, and networking events worldwide. Career Opportunities GPCR job listings, career tips, and networking opportunities in the field. Read the Free Edition Here's a preview of what you'll find in our latest newsletter Better GPCR Drug Discovery Decisions Start With Structured Learning The Dr. GPCR University has undergone a structural redesign. This is a focused soft launch—prioritizing usability, clarity, and strategic navigation. You can now search courses by level, topic, or instructor. Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages. Full course videos stream directly from the platform, and downloadable resources are available in one place. Dr. GPCR News 3 min read Get Premium for Full Access Latest Issues Sharpening GPCR Drug Discovery Decisions Read Full Issue Feb 6 - 12, 2026 A New Era for the Dr. GPCR Ecosystem—Built for What Comes Next Read Full Issue Dec 19 - Feb 5, 2026 Binding Affinity, Measured With Confidence — Closing Out 2025 Read Full Issue Dec 12 - 18, 2025 2025 Wrap-Up : A Year of Progress Across the GPCR Community Read Full Issue Dec 5 - 11, 2025 How System-Level GPCR Insights Strengthen Every Discovery Decision Read Full Issue November 21 - December 4, 2025 Schild Truths & Incretin Insights — This Week in GPCRs Read Full Issue November 14 - 20, 2025 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 ... 9 About GPCR Weekly News GPCR Weekly News was launched in 2020 as part of the Dr. GPCR initiative. Our mission is to provide timely, relevant, and accessible information to scientists and industry professionals working in GPCR research and drug discovery. Every week, our team curates the most important developments so you never miss a breakthrough, opportunity, or event that could impact your work. Learn More about DrGPCR Unlock Premium 🔥 Upgrade to Premium Premium Yearly $499 $ 499 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. 🔒 Grandfather Guarantee, your rate never increases Ready to Stay Ahead in GPCR Research? Join scientists worldwide who rely on GPCR Weekly News for the latest insights and opportunities.